Delivery Order SPE2DB25D3005-SPE2DB25FQGCE
Award Date 6/18/25
Potential Completion Date 6/20/25
Potential Value $6K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a $30,729.94 delivery order to AmerisourceBergen Drug Corp for ENBREL 50 mg/ml syringes, with an ultimate completion date of July 25, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at the awardee's facility in Conshohocken, Pennsylvania. ENBREL is a biologic immunosuppressant medication commonly used to treat rheumatoid arthritis and other autoimmune conditions, indicating this procurement...
- The Defense Logistics Agency awarded a delivery order valued at $41,484.36 to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/ml syringes. This firm fixed-price, competitively awarded contract (no set-aside used) is scheduled for completion by November 6, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. Enbrel is a critical biologic medication used primarily for treating rheumatoid arthritis and other autoimmune conditions,...
- The Defense Logistics Agency awarded a delivery order valued at $15,447.06 to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/ml syringes. This non-competitive, firm fixed-price delivery order was issued on November 3, 2025, with an ultimate completion date of November 4, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. Enbrel is a biologic medication used to treat autoimmune conditions including rheumatoid arthritis, and this...
- The Defense Logistics Agency awarded a $31,043.90 firm fixed-price delivery order to AmerisourceBergen Drug Corp for ENBREL 50 mg/ml syringes, with an ultimate completion date of September 5, 2025. This non-set-aside award was made competitively and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.9 billion vehicle running through December 2026. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a $5,580.50 delivery order to AmerisourceBergen Drug Corp on May 28, 2025, for the supply of ENBREL 50 mg/ml syringes. This contract represents a firm fixed-price delivery order with an ultimate completion date of May 29, 2025, and is classified as a non-set-aside award. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. ENBREL is a biologic pharmaceutical used in the treatment of rheumatoid arthritis and other...
- The Defense Logistics Agency awarded a delivery order valued at $20,608.70 to AmerisourceBergen Drug Corp for ENBREL 50 mg/mL syringes, with an ultimate completion date of August 12, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the prime contractor. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company serves as a major pharmaceutical distributor and critical vendor for...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Enbrel 50 mg/ml syringes valued at $68,950.48 on September 12, 2025, with completion targeted for September 15, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which carries a $999,999,999.00 ceiling and extends through December 2026. The place of...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $13,396.39 for ENBREL 50 mg/mL syringes on April 24, 2025, with completion scheduled for April 25, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. ENBREL (etanercept) is a biologic immunosuppressant used to treat rheumatoid arthritis, psoriasis, and other inflammatory...
- The Defense Logistics Agency awarded a $72,895.88 delivery order to AmerisourceBergen Drug Corp for ENBREL 50 mg/mL syringes, with an ultimate completion date of August 8, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded through the federal procurement process. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major...
- The Defense Logistics Agency awarded a $17,257.88 delivery order to AmerisourceBergen Drug Corp on June 9, 2025, for the supply of Enbrel 50 mg/ml syringes. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an...